Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
コンテンツは Proactive Investors によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Proactive Investors またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Player FM -ポッドキャストアプリ
Player FMアプリでオフラインにしPlayer FMう!
Player FMアプリでオフラインにしPlayer FMう!
Recce Pharmaceuticals reaches midpoint in Phase II Trial for Topical Gel R327G
Manage episode 444249215 series 2891889
コンテンツは Proactive Investors によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Proactive Investors またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) CEO James Graham joins Proactive’s Tylah Tully to discuss progress in a Phase II clinical trial for the topical gel RECCE® 327 (R327G). Recce has formally reached the halfway point, with 15 patients successfully dosed. The trial is assessing the efficacy of R327G against Acute Bacterial Skin and Skin Structure Infections (ABSSSI), including diabetic foot infections and other wound infections, which are areas of significant unmet medical need. Early data shows that R327G is well tolerated, with promising antibacterial effects observed across a range of infections. The trial aims to enrol 30 participants by the end of 2024. The clinical study locations have expanded, now including Barwon Health, Australian Clinical Research Network NSW and ACRN Melbourne, increasing access to this novel treatment. The global ABSSSI market was valued at US$1.34 billion in 2023 and is projected to grow to US$2.31 billion over the next decade. An interim clinical review is scheduled for mid-October 2024 with further results expected shortly thereafter. Graham expressed optimism about the trial’s progress and the potential impact of R327G on the growing global healthcare need for effective treatments against drug-resistant bacterial infections. #ProactiveInvestors #ReccePharmaceuticals #ASX #R327G #Phase2Trial #ABSSSI #WoundInfections #DiabeticFootInfections #ClinicalTrial #AntibacterialGel #BroadSpectrumAntimicrobial #SkinInfections #DrugResistantBacteria #HealthcareInnovation #BarwonHealth #ClinicalResearch #Australia #InfectiousDiseases #BacterialInfections #MedicalResearch #Biotechnology #TGA #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 つのエピソード
Manage episode 444249215 series 2891889
コンテンツは Proactive Investors によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Proactive Investors またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) CEO James Graham joins Proactive’s Tylah Tully to discuss progress in a Phase II clinical trial for the topical gel RECCE® 327 (R327G). Recce has formally reached the halfway point, with 15 patients successfully dosed. The trial is assessing the efficacy of R327G against Acute Bacterial Skin and Skin Structure Infections (ABSSSI), including diabetic foot infections and other wound infections, which are areas of significant unmet medical need. Early data shows that R327G is well tolerated, with promising antibacterial effects observed across a range of infections. The trial aims to enrol 30 participants by the end of 2024. The clinical study locations have expanded, now including Barwon Health, Australian Clinical Research Network NSW and ACRN Melbourne, increasing access to this novel treatment. The global ABSSSI market was valued at US$1.34 billion in 2023 and is projected to grow to US$2.31 billion over the next decade. An interim clinical review is scheduled for mid-October 2024 with further results expected shortly thereafter. Graham expressed optimism about the trial’s progress and the potential impact of R327G on the growing global healthcare need for effective treatments against drug-resistant bacterial infections. #ProactiveInvestors #ReccePharmaceuticals #ASX #R327G #Phase2Trial #ABSSSI #WoundInfections #DiabeticFootInfections #ClinicalTrial #AntibacterialGel #BroadSpectrumAntimicrobial #SkinInfections #DrugResistantBacteria #HealthcareInnovation #BarwonHealth #ClinicalResearch #Australia #InfectiousDiseases #BacterialInfections #MedicalResearch #Biotechnology #TGA #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 つのエピソード
Semua episod
×プレーヤーFMへようこそ!
Player FMは今からすぐに楽しめるために高品質のポッドキャストをウェブでスキャンしています。 これは最高のポッドキャストアプリで、Android、iPhone、そしてWebで動作します。 全ての端末で購読を同期するためにサインアップしてください。